A unified approach to evaluating cellular immunotherapy in solid organ transplantation

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: A unified approach to evaluating cellular immunotherapy in solid organ transplantation
Project Number: CORDIS-96748
Project web address: Follow on CORDIS
Organization: Klinikum Der Universitaet Regensburg, Germany, Regensburg
Collaborators: King'S College London, GB
Regents Of The University Of California, US
University Of Wisconsin-Madison, US
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
Loughborough University, GB
Fondazione Centro San Raffaele Del Monte Tabor, IT
Centre Hospitalier Universitaire De Nantes, FR
Miltenyi Biotec Gmbh, DE
Fondazione Centro San Raffaele, IT
Deutsches Rheuma-Forschungszentrum Berlin, Ein Leibniz-Institut, DE
Alta Ricerca E Sviluppo In Biotecnologie S.R.L.U., IT
The General Hospital Corporation, US
Clinit Ag, DE
Electro Scientific Industries Europe Ltd., GB
Pharmatching Gmbh, DE
Principal Investigators (PI): Paul Labbett, GB
Mario Valsecchi, IT
Linda Polik, GB
Eveline Fräßdorf, DE
Michael Apel, DE
Elisabeth Geiger, DE
Cristiana Tozzi, IT
Anne Brethet, FR
Maria Rosa Pedrazzi, IT
Louise Denniff, GB
Natascha Heifer, DE
Kevin R Kaier, US
Damon Green, GB
Robert Andresen, US
Sabine Kistner, DE
Anthony Cassese, US
 
Project Description:
Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. Reducing the need for immunosuppression would dramatically improve the outcome for transplant recipients and reduce health costs for society. The means to achieve this goal has not been realised with pharmacological or biological agents yet. Conditioning the immune response of solid organ transplant recipients towards allograft acceptance using cell-based therapies is now becoming technically feasible and clinically promising. The central focus of our proposed cooperative work programme is to produce distinct populations of haematopoietic regulatory cells and comparatively test their safety and efficacy in minimising pharmacological immunosuppression in solid organ transplantation. Preparations of regulatory T cells, macrophages and dendritic cells will be licensed for clinical manufacture in outstanding research facilities across Europe, and subsequently, these different tolerance-promoting cell types will be assessed in a single Phase I/II clinical study for safety, clinical practicality and efficacy. The therapeutic potential of these cells will be directly compared using one, single clinical protocol. In addition, we will study the tolerogenic characteristics of these regulatory cell types at in-depth molecular and functional levels. These integrative, but very focused, research plans are expected to result in the identification of the most promising regulatory cell products for further testing, and commercial exploitation: the final outcome is to identify a cell product which has genuine potential to induce operational tolerance if correctly applied in a Phase IIb clinical trial. This objective can only be accomplished by the cooperation of the most experienced researchers in this field across Europe, in alliance with SMEs devoted to cell therapy.
 
Project Terms:
medical biotechnology medicine and health
Project Title: A unified approach to evaluating cellular immunotherapy in solid organ transplantation
Project Number: CORDIS-96748
Project web address: Follow on CORDIS
Organization: Klinikum Der Universitaet Regensburg, Germany, Regensburg
Collaborators: King'S College London, GB
Regents Of The University Of California, US
University Of Wisconsin-Madison, US
The Chancellor, Masters And Scholars Of The University Of Oxford, GB
Loughborough University, GB
Fondazione Centro San Raffaele Del Monte Tabor, IT
Centre Hospitalier Universitaire De Nantes, FR
Miltenyi Biotec Gmbh, DE
Fondazione Centro San Raffaele, IT
Deutsches Rheuma-Forschungszentrum Berlin, Ein Leibniz-Institut, DE
Alta Ricerca E Sviluppo In Biotecnologie S.R.L.U., IT
The General Hospital Corporation, US
Clinit Ag, DE
Electro Scientific Industries Europe Ltd., GB
Pharmatching Gmbh, DE
Principal Investigators (PI): Paul Labbett, GB
Mario Valsecchi, IT
Linda Polik, GB
Eveline Fräßdorf, DE
Michael Apel, DE
Elisabeth Geiger, DE
Cristiana Tozzi, IT
Anne Brethet, FR
Maria Rosa Pedrazzi, IT
Louise Denniff, GB
Natascha Heifer, DE
Kevin R Kaier, US
Damon Green, GB
Robert Andresen, US
Sabine Kistner, DE
Anthony Cassese, US
 
Project Categories:
Natural Sciences > Anti-aging strategies > Bioengineering & regeneration > Stem cells > Autologous Stem Cells
 
Other Information:
Fiscal Year: 2010
Project Start Date: 1 November 2010
Project End Date: 31 October 2017
Project program: FP7-HEALTH
 
Project Funding Information:
Funding Mechanism: CP-IP - Large-scale integrating project
Year Funding Organization Total Funding, $
2010 European Research Council $16,092,330